Article
Medicine, General & Internal
Guilherme Nader Marta, Leonardo G. da Fonseca, Maria Ignez Braghiroli, Fernando Moura, Paulo M. Hoff, Jorge Sabbaga
Summary: This study evaluated the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma, showing no significant differences in outcomes between younger and older patients. Age alone should not restrict clinical decision-making for patients with advanced HCC.
Review
Oncology
Yongsheng Pang, Aydin Eresen, Zigeng Zhang, Qiaoming Hou, Yining Wang, Vahid Yaghmai, Zhuoli Zhang
Summary: Sorafenib is an approved oral medication for treating unresectable hepatocellular carcinoma. It targets growth factor receptors to reduce angiogenesis and inhibits cell proliferation. However, its effectiveness is limited and it can cause significant toxicities.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Review
Medicine, Research & Experimental
Fan-Hua Kong, Qi-Fa Ye, Xiong-Ying Miao, Xi Liu, Si-Qi Huang, Li Xiong, Yu Wen, Zi-Jian Zhang
Summary: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and has high resistance to traditional chemotherapy. Sorafenib, an oral kinase inhibitor, has shown improved survival rates for advanced liver cancer patients, but its clinical application is limited by poor solubility and low bioavailability. Nanoparticles have been explored to enhance the therapeutic efficacy of sorafenib in treating HCC, offering new hope for liver cancer treatment.
Review
Oncology
Jia Luo, Benjian Gao, Zhiyu Lin, Hua Fan, Wen Ma, Danfei Yu, Qian Yang, Jing Tian, Xiaoli Yang, Bo Li
Summary: This meta-analysis compares the efficacy and safety of lenvatinib and sorafenib in patients with advanced hepatocellular carcinoma (HCC). The results showed that lenvatinib had significantly better progression-free survival and disease control rate compared to sorafenib, with similar incidences of adverse events. Lenvatinib is a promising alternative to sorafenib as a first-line therapy for advanced HCC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yoshimichi Haruna, Takayuki Yakushijin, Seiichi Kawamoto
Summary: The study confirmed that dosing vitamin K alongside sorafenib can significantly enhance its anticancer effects against hepatocellular carcinoma, leading to improved objective response rate and progression-free survival time. Patients who received vitamin K in addition to sorafenib also showed significantly extended overall survival time, especially those who achieved complete or partial response.
Article
Oncology
Anna Soria, Mariona Calvo, Meritxell Casas, Zara Vidales, Sergio Munoz-Martinez, Victor Sapena, Marc Puigvehi, Lidia Canillas, Raquel Guardeno, Adolfo Gallego, Beatriz Minguez, Diana Horta, Ariadna Clos, Silvia Montoliu, Merce Roget, Maria Reig, Mercedes Vergara
Summary: This study characterized elderly patients treated with sorafenib and found that it is safe for this population. The findings provide valuable information for the use of atezolizumab-bevacizumab in elderly candidates.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Thorben W. Fruendt, Christian Casar, Johann von Felden, Ulrike Schoeler, Maximilian Priebe, Jenny Kraczyk, Hannes Ahrend, Johannes Salamon, Gerhard Adam, Samuel Huber, Ansgar W. Lohse, Henning Wege, Kornelius Schulze
Summary: This retrospective study investigated the tolerability and survival outcomes of elderly patients receiving palliative treatment for hepatocellular carcinoma (HCC). The results showed that elderly patients tolerated palliative treatment well and had similar overall survival to younger patients. This suggests that regular palliative treatment should be considered for elderly HCC patients, despite their age.
Article
Medicine, Research & Experimental
Jialiang Luo, Lei Li, Zhengyumeng Zhu, Bo Chang, Fan Deng, Di Wang, Xiao Lu, Daming Zuo, Qingyun Chen, Jia Zhou
Summary: This study demonstrated that the combination of fucoidan and sorafenib could overcome sorafenib resistance in hepatocellular carcinoma cells by interacting with cell membrane EGFR and suppressing EGFR redistribution and downstream signaling. The simultaneous treatment of fucoidan and sorafenib might serve as a potential therapeutic strategy against sorafenib-resistant HCC.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Oncology
Zhonghao Jiang, Chaoliu Dai
Summary: Liver cancer is a highly malignant disease with low sensitivity to chemotherapy, and the prognosis for patients is poor. Sorafenib has been the only first-line therapeutic agent for advanced hepatocellular carcinoma (HCC) until the discovery of lenvatinib. However, many HCC patients are insensitive to sorafenib, and the overall efficacy of the drug is unsatisfactory. This study reviews the potential mechanisms of sorafenib resistance and summarizes combination therapies and potential drugs that can sensitize HCC cells to sorafenib based on previous studies and reports.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2023)
Article
Immunology
Yamin Shu, Ying Tang, Yufeng Ding, Qilin Zhang
Summary: This study aimed to evaluate the cost-effectiveness of nivolumab vs sorafenib as first-line therapy for advanced HCC from the perspective of Chinese healthcare system. The results showed that nivolumab could provide more health benefits compared with sorafenib, but was estimated not to be cost-effective at the commonly adopted WTP threshold in China.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Qinqin Liu, Nan You, Jing Li, Ke Wu, Xuehui Peng, Zheng Wang, Liang Wang, Yinan Zhu, Lu Zheng
Summary: The study found that the combination of camrelizumab and sorafenib significantly improved the overall response rate and progression-free survival of patients with advanced HCC, but had no significant impact on overall survival. The combination therapy group exhibited more adverse events in terms of efficacy, but most of these adverse events were easily controlled after treatment. Further prospective randomized trials are needed to confirm the potential clinical benefits of this combination therapy.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Shenglan Huang, Dan Li, LingLing Zhuang, Liying Sun, Jianbing Wu
Summary: This meta-analysis explored the efficacy and safety of sorafenib in hepatocellular carcinoma patients after radical surgery, revealing that sorafenib can improve overall survival, recurrence-free survival, and reduce recurrence rates without intolerable side effects. More evidence is needed for a definitive conclusion.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Ann-Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim, Ho Yeong Lim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn
Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.
JOURNAL OF HEPATOLOGY
(2022)
Article
Materials Science, Multidisciplinary
Peifeng Wang, Yang Du, Xingyang Zhao, Yueyang Hu, Tianjun Zhou, Xiaolong Liang, Chihua Fang, Jie Tian
Summary: A multifunctional mesoporous polydopamine nanoprobe was designed for targeted therapy of hepatocellular carcinoma. The nanoprobes can be tracked and monitored in real-time during the treatment process by their magnetic resonance imaging/fluorescence/photoacoustic tri-modal imaging ability. This provides a new imaging-guided synergic treatment for hepatocellular carcinoma, improving the long-term therapeutic effects of sorafenib.
MATERIALS & DESIGN
(2023)
Article
Oncology
Xiaomi Li, Xiaoyan Ding, Wei Li, Jinglong Chen
Summary: This study suggests that the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) is more effective and well tolerated than mono-TKIs in patients with hepatocellular carcinoma (HCC) who have failed sorafenib (SOR) treatment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, Anna Viola, Alfredo Abbruzzese, Maria Cappello, Enrica Giuffrida, Lucio Carrozza, Antonino Carlo Privitera, Antonio Magnano, Concetta Ferracane, Giuseppe Scalisi, Maria Giovanna Minissale, Emiliano Giangreco, Serena Garufi, Carmelo Bertolami, Ugo Cucinotta, Francesco Graziano, Angelo Casa, Sara Renna, Giulia Teresi, Giulia Rizzuto, Mariella Mannino, Marcello Maida, Ambrogio Orlando
Summary: This retrospective study found that severe inflammatory bowel disease was an independent risk factor for severe COVID-19. Patients with inflammatory bowel disease did not have a higher risk of SARS-CoV-2 infection compared to the general population, and a worse prognosis was not typically associated with immunomodulatory drugs.
INFLAMMATORY BOWEL DISEASES
(2023)
Editorial Material
Gastroenterology & Hepatology
Giuseppe Cabibbo, Jordi Bruix
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
M. Maida, M. Ventimiglia, A. Facciorusso, A. Vitello, E. Sinagra, G. Marasco
Summary: This meta-analysis evaluated the effectiveness and safety of 1-L PEG-ASC compared to other bowel preparations for colonoscopy. The results showed that 1-L PEG-ASC had higher cleansing success and right-colon high-quality cleansing rates compared to other preparations, with similar adenoma detection rates. However, the incidence of adverse events was higher with 1-L PEG-ASC, although no serious adverse events or deaths occurred.
DIGESTIVE AND LIVER DISEASE
(2023)
Review
Gastroenterology & Hepatology
Daryl Ramai, Ikponmwosa Enofe, Smit S. Deliwala, Daniel Mozell, Antonio Facciorusso, Paraskevas Gkolfakis, Babu P. Mohan, Saurabh Chandan, Melissa Previtera, Marcello Maida, Andrea Anderloni, Douglas G. Adler, Andrew Ofosu
Summary: This study aimed to evaluate the clinical efficacy and safety of early (<4 weeks) and standard (>= 4 weeks) endoscopic ultrasound-guided drainage of pancreatic fluid collections. The results showed that there were similar technical and clinical outcomes between early and standard drainage, suggesting that delaying endoscopic drainage for 4 weeks may not be necessary.
GASTROINTESTINAL ENDOSCOPY
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Takumi Kawaguchi, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Antonella Cammarota, Valentina Burgio, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study compares the response rates of lenvatinib and atezolizumab plus bevacizumab in the first-line treatment of hepatocellular carcinoma (HCC) patients. The results show that lenvatinib achieves higher response rates in all patient subgroups. Patients who achieve complete response with atezolizumab plus bevacizumab can achieve a better overall survival compared to other treatments.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Rodolfo Sacco, Daryl Ramai, Raffaella Tortora, Giovan Giuseppe di Costanzo, Michela Emma Burlone, Mario Pirisi, Piera Federico, Bruno Daniele, Marianna Silletta, Paolo Gallo, Caterina Cocuzza, Maurizio Russello, Giuseppe Cabibbo, Gabriele Rancatore, Silvia Cesario, Gianluca Masi, Luca Marzi, Andrea Mega, Alessandro Granito, Giulia Pieri, Edoardo G. G. Giannini, Rosa Paolillo, Gennaro Gadaleta-Caldarola, Vincenzo Dadduzio, Guido Giordano, Luca Giacomelli, Simonetta Papa, Matteo Renzulli, Marcello Maida, Michele Ghidini, Mauro Borzio, Antonio Facciorusso
Summary: Hepatocellular carcinoma is the fifth most common cancer worldwide. Lenvatinib has proven to be an effective option for treating advanced diseases. Our study showed that patients with nonviral etiologies have longer survival than those with viral etiology, which is important for clinical decision-making.
Article
Gastroenterology & Hepatology
Daryl Ramai, Dan M. McEntire, Kameron Tavakolian, Joseph Heaton, Saurabh Chandan, Banreet Dhindsa, Amaninder Dhaliwal, Marcello Maida, Andrea Anderloni, Antonio Facciorusso, Douglas G. Adler
Summary: This study compared the safety and outcomes of endoscopic, percutaneous, and surgical necrosectomy for pancreatic necrosis. The findings showed that endoscopic necrosectomy had the lowest mortality rate and fewer complications, shorter hospital stays, and lower costs compared to percutaneous and surgical approaches.
ENDOSCOPY INTERNATIONAL OPEN
(2023)
Editorial Material
Gastroenterology & Hepatology
Matthias Pinter, Maria Reig, Giuseppe Cabibbo
Letter
Gastroenterology & Hepatology
Loreta A. Kondili, Maria Grazia Rumi, Antonio Craxi
JOURNAL OF HEPATOLOGY
(2023)
Review
Oncology
Socrate Pallio, Stefano Francesco Crino, Marcello Maida, Emanuele Sinagra, Vincenzo Francesco Tripodi, Antonio Facciorusso, Andrew Ofosu, Maria Cristina Conti Bellocchi, Endrit Shahini, Giuseppinella Melita
Summary: Endoscopic ultrasound is a valuable technique for evaluating subepithelial lesions and determining their malignancy. Gastrointestinal Stromal Tumors (GISTs) require differential diagnosis due to their potential malignant behavior. Conventional endoscopic ultrasound may have difficulties distinguishing GISTs from other subepithelial lesions, but recent advancements in enhanced modalities and artificial intelligence systems have improved diagnostic accuracy.
Review
Oncology
Apostolis Papaefthymiou, Gavin J. Johnson, Marcello Maida, Paraskevas Gkolfakis, Daryl Ramai, Antonio Facciorusso, Marianna Arvanitakis, Alexander Ney, Giuseppe K. Fusai, Adrian Saftoiu, Daniela Tabacelia, Simon Phillpotts, Michael H. Chapman, George J. Webster, Stephen P. Pereira
Summary: Pancreatic cystic lesions are increasingly diagnosed and have become a significant condition in clinical practice. Endoscopic ultrasound (EUS) provides an additional therapeutic tool for treating these lesions. EUS-guided ablation techniques, particularly the combination of ethanol and paclitaxel injection, demonstrate promising efficacy and safety in treating pancreatic cystic lesions.
Review
Medicine, General & Internal
Daryl Ramai, Viraaj Pannu, Antonio Facciorusso, Banreet Dhindsa, Joseph Heaton, Andrew Ofosu, Saurabh Chandan, Marcello Maida, Barbara Lattanzi, Eduardo Rodriguez, Vicky H. Bhagat, Jayanta Samanta, Monique T. Barakat
Summary: In recent years, endoscopic-ultrasound-guided liver biopsy (EUS-LB) has emerged as an effective alternative to traditional liver biopsy techniques. Comparative studies have shown that both endoscopic and non-endoscopic approaches have similar diagnostic adequacy, accuracy, and adverse events, but EUS-LB offers the advantage of reduced recovery time. EUS-LB allows sampling of both lobes of the liver and enables portal pressure measurements, but cost-effectiveness may be a concern.
Review
Medicine, General & Internal
Socrate Pallio, Giuseppinella Melita, Endrit Shahini, Alessandro Vitello, Emanuele Sinagra, Barbara Lattanzi, Antonio Facciorusso, Daryl Ramai, Marcello Maida
Summary: Acute variceal bleeding is a serious complication of portal hypertension and a common cause of acute upper gastrointestinal bleeding. It represents a major economic and population health issue.
Article
Oncology
Ciro Celsa, Giuseppe Cabibbo, David James Pinato, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Paolo Giuffrida, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Calogero Camma
Summary: Atezolizumab+Bevacizumab is the standard of care for first-line treatment of advanced HCC. However, there is a lack of direct comparison with other combination treatments including ICI+TKI. This network meta-analysis aims to indirectly compare the efficacy and safety of first-line systemic therapies for unresectable-advanced HCC.
